Vireo Growth Inc. announced a strong Q3 2026 financial performance with GAAP revenue of $253.7 million, a 177% increase year-over-year, fueled by recent acquisitions including C21 Investments and PharmaCann assets. The company achieved a gross profit of $107.8 million and an adjusted EBITDA of $42.7 million, reflecting its consolidation strategy and expanded market presence across 15 states with about 270 dispensaries. Vireo also launched a share repurchase program and secured new financing, ending the quarter with $106.8 million in cash. Looking ahead, the company projects Q4 2026 revenue between $250 million and $265 million and expects continued growth through further acquisitions and integration efforts.
Vireo Growth Inc.'s third quarter 2026 results show a remarkable 177% year-over-year revenue increase to $253.7 million. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Nov 10, 2026 18:41 WIB: out of 83 priced US stocks, 26 rose and 54 fell. Notable movers include AG at USD 15.45 with a -2.65% change, CDE at USD 16.02 down 2.61%, and IAG at USD 19.34 down 2.52% with 100% buy order activity and a typical hold time of 13 days on Pluang.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
